查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1418351

Daptomycin市场报告：2030 年趋势、预测与竞争分析

Daptomycin Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 - page report | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

Daptomycin趋势和预测

预计2024年至2030年，全球Daptomycin市场将以4.5%的复合年增长率成长。这个市场的主要驱动因素是遭受皮肤和皮肤组织感染疾病的人口不断增加、抗菌剂的使用不断增加，以及败血症等血液感染疾病的增加。全球Daptomycin市场前景广阔，300mg和500mg市场有未来性。

Daptomycin市场洞察

Lucintel 预计，由于研发倡议的活性化，复杂皮肤组织感染疾病在预测期内仍将占据更大的份额。

我们相信，由于其功效和稳定性，500mg 将继续成为该市场的一大细分市场。

由于多项政府措施的兴起，北美将在预测期内保持最大的市场规模。

常问问题

Q1.市场成长预测如何？

A1. 2024年至2030年，全球Daptomycin市场预计将以4.5%的复合年增长率成长。

Q2.影响市场成长的主要驱动因素有哪些？

A2. 该市场的主要驱动力是遭受皮肤和皮肤组织感染疾病的人口不断增加，其作为抗菌剂的使用不断增加，以及脓毒症等血液感染疾病的增加。

Q3.市场的主要细分市场有哪些？

A3.Daptomycin市场未来性，300mg和500mg市场机会庞大。

Q4.市场上主要企业有哪些？

A4. 生产Daptomycin的主要企业如下。

  • Teva Pharmaceuticals Industries
  • Merck
  • Cipla
  • Pfizer
  • BE Pharmaceuticals
  • Reddy'S Laboratories
  • Mylan
  • Fresenius Kabi
  • Nichi-Iko Pharmaceutical
  • Novo Holdings

Q5.未来最大的细分市场是什么？

A5.Lucintel 预计，由于研发倡议的加强，复杂性皮肤组织感染疾病在预测期内仍将占据更大的份额。

Q6. 未来五年预计哪个地区将成为最大的市场？

A6. 由于多项政府措施，北美在预测期内仍将是最大的。

Q7. 可以客製化报告吗？

A7. 是的，Lucintel 提供 10% 的客製化服务，无需额外费用。

目录

第一章执行摘要

第二章全球Daptomycin市场：市场动态

  • 简介、背景、分类
  • 供应链
  • 产业驱动因素与挑战

第三章 2018-2030年市场趋势及预测分析

  • 宏观经济趋势（2018-2023）与预测（2024-2030）
  • 全球Daptomycin市场趋势（2018-2023）与预测（2024-2030）
  • 全球Daptomycin市场（按适应症）
    • 复杂的皮肤组织感染疾病
    • 菌血症
  • 按年龄组别分類的全球Daptomycin市场
    • 儿童
    • 成人
  • 全球Daptomycin市场实力
    • 300mg
    • 500mg

第四章 2018-2030年区域市场趋势及预测分析

  • 全球Daptomycin市场区域分布
  • 北美Daptomycin市场
  • 欧洲Daptomycin市场
  • 亚太达托Daptomycin市场
  • 其他地区Daptomycin市场

第五章 竞争分析

  • 产品系列分析
  • 营运整合
  • 波特五力分析

第六章 成长机会与策略分析

  • 成长机会分析
    • 全球Daptomycin市场成长机会（按适应症）
    • 按年龄组别分類的全球Daptomycin市场成长机会
    • 全球Daptomycin市场成长机会（按优势）
    • 全球Daptomycin市场成长机会（按地区）
  • 全球Daptomycin市场的新趋势
  • 战略分析
    • 新产品开发
    • 全球Daptomycin市场产能扩张
    • 全球Daptomycin市场的併购和合资企业
    • 认证和许可

第七章主要企业概况

  • Teva Pharmaceuticals Industries
  • Merck
  • Cipla
  • Pfizer
  • BE Pharmaceuticals
  • Reddy's Laboratories
  • Mylan
  • Fresenius Kabi
  • Nichi-Iko Pharmaceutical
  • Novo Holdings
简介目录

Daptomycin Trends and Forecast

The future of the global daptomycin market looks promising with opportunities in the 300mg and 500mg markets. The global daptomycin market is expected to grow with a CAGR of 4.5% from 2024 to 2030. The major drivers for this market are increasing population affected by skin and skin structure infections and expanding application as an antibacterial agent, and increasing bloodstream infections, such as sepsis.

A more than 150-page report is developed to help in your business decisions.

Daptomycin by Segment

The study includes a forecast for the global daptomycin by indication, age group , strength, and region.

Daptomycin Market by Indication [Shipment Analysis by Value from 2018 to 2030]:

  • Complicated Skin Structure Infections
  • Bacteremia

Daptomycin Market by Age Group [Shipment Analysis by Value from 2018 to 2030]:

  • Pediatric
  • Adult

Daptomycin Market by Strength [Shipment Analysis by Value from 2018 to 2030]:

  • 300mg
  • 500mg

Daptomycin Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Daptomycin Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies daptomycin companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the daptomycin companies profiled in this report include-

  • Teva Pharmaceuticals Industries
  • Merck
  • Cipla
  • Pfizer
  • BE Pharmaceuticals
  • Reddy'S Laboratories
  • Mylan
  • Fresenius Kabi
  • Nichi-Iko Pharmaceutical
  • Novo Holdings

Daptomycin Market Insights

Lucintel forecasts that complicated skin structure infections will remain the larger segment over the forecast period due to heightened research and development initiatives.

Within this market, 500mg will remain the larger segment due to its efficacy and stability.

North America will remain the largest over the forecast period due to growing several government initiatives.

Features of the Global Daptomycin Market

Market Size Estimates: Daptomycin market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Daptomycin market size by indication, age group , strength, and region in terms of value ($B).

Regional Analysis: Daptomycin market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different indication, age group , strength, and regions for the daptomycin market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the daptomycin market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the growth forecast for daptomycin market?

Answer: The global daptomycin market is expected to grow with a CAGR of 4.5% from 2024 to 2030.

Q2. What are the major drivers influencing the growth of the daptomycin market?

Answer: The major drivers for this market are increasing population affected by skin and skin structure infections and expanding application as an antibacterial agent, and increasing bloodstream infections, such as sepsis.

Q3. What are the major segments for daptomycin market?

Answer: The future of the daptomycin market looks promising with opportunities in the 300mg and 500mg markets.

Q4. Who are the key daptomycin market companies?

Answer: Some of the key daptomycin companies are as follows.

  • Teva Pharmaceuticals Industries
  • Merck
  • Cipla
  • Pfizer
  • BE Pharmaceuticals
  • Reddy'S Laboratories
  • Mylan
  • Fresenius Kabi
  • Nichi-Iko Pharmaceutical
  • Novo Holdings

Q5. Which daptomycin market segment will be the largest in future?

Answer: Lucintel forecasts that complicated skin structure infections will remain the larger segment over the forecast period due to heightened research and development initiatives.

Q6. In daptomycin market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest over the forecast period due to growing several government initiatives.

Q7. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the daptomycin market by indication (complicated skin structure infections and bacteremia), age group (pediatric and adult), strength (300mg and 500mg), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Daptomycin Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Daptomycin Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Daptomycin Market by Indication
    • 3.3.1: Complicated skin structure infections
    • 3.3.2: Bacteremia
  • 3.4: Global Daptomycin Market by Age Group
    • 3.4.1: Pediatric
    • 3.4.2: Adult
  • 3.5: Global Daptomycin Market by Strength
    • 3.5.1: 300mg
    • 3.5.2: 500mg

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Daptomycin Market by Region
  • 4.2: North American Daptomycin Market
    • 4.2.2: North American Daptomycin Market by Strength: 300mg and 500mg
  • 4.3: European Daptomycin Market
    • 4.3.1: European Daptomycin Market by Indication: Complicated skin structure infections and Bacteremia
    • 4.3.2: European Daptomycin Market by Strength: 300mg and 500mg
  • 4.4: APAC Daptomycin Market
    • 4.4.1: APAC Daptomycin Market by Indication: Complicated skin structure infections and Bacteremia
    • 4.4.2: APAC Daptomycin Market by Strength: 300mg and 500mg
  • 4.5: ROW Daptomycin Market
    • 4.5.1: ROW Daptomycin Market by Indication: Complicated skin structure infections and Bacteremia
    • 4.5.2: ROW Daptomycin Market by Strength: 300mg and 500mg

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Daptomycin Market by Indication
    • 6.1.2: Growth Opportunities for the Global Daptomycin Market by Age Group
    • 6.1.3: Growth Opportunities for the Global Daptomycin Market by Strength
    • 6.1.4: Growth Opportunities for the Global Daptomycin Market by Region
  • 6.2: Emerging Trends in the Global Daptomycin Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Daptomycin Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Daptomycin Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Teva Pharmaceuticals Industries
  • 7.2: Merck
  • 7.3: Cipla
  • 7.4: Pfizer
  • 7.5: BE Pharmaceuticals
  • 7.6: Reddy's Laboratories
  • 7.7: Mylan
  • 7.8: Fresenius Kabi
  • 7.9: Nichi-Iko Pharmaceutical
  • 7.10: Novo Holdings